These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 34697277)

  • 1. Effects of Switching from Fenofibrate to Pemafibrate for Asymptomatic Primary Biliary Cholangitis.
    Dohmen K; Onohara SY; Harada S
    Korean J Gastroenterol; 2021 Oct; 78(4):227-234. PubMed ID: 34697277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis.
    Dohmen K; Tanaka H; Haruno M
    Fukuoka Igaku Zasshi; 2013 Oct; 104(10):350-61. PubMed ID: 24511666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fenofibrate for patients with asymptomatic primary biliary cirrhosis.
    Dohmen K; Mizuta T; Nakamuta M; Shimohashi N; Ishibashi H; Yamamoto K
    World J Gastroenterol; 2004 Mar; 10(6):894-8. PubMed ID: 15040040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score.
    Hegade VS; Khanna A; Walker LJ; Wong LL; Dyson JK; Jones DEJ
    Dig Dis Sci; 2016 Oct; 61(10):3037-3044. PubMed ID: 27435324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases.
    Yamashita S; Masuda D; Matsuzawa Y
    Curr Atheroscler Rep; 2020 Jan; 22(1):5. PubMed ID: 31974794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA.
    Duan W; Ou X; Wang X; Wang Y; Zhao X; Wang Q; Wu X; Zhang W; Ma H; You H; Jia J
    Rev Esp Enferm Dig; 2018 Sep; 110(9):557-563. PubMed ID: 29739227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Additional fibrate treatment in UDCA-refractory PBC patients.
    Chung SW; Lee JH; Kim MA; Leem G; Kim SW; Chang Y; Lee HY; Yoon JS; Park JY; Lee YB; Cho EJ; Yu SJ; Kim YJ; Yoon JH
    Liver Int; 2019 Sep; 39(9):1776-1785. PubMed ID: 31162879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fenofibrate normalizes alkaline phosphatase and improves long-term outcomes in patients with advanced primary biliary cholangitis refractory to ursodeoxycholic acid.
    Ding D; Ren P; Guo G; Liu Y; Yang C; Zheng L; Jia G; Deng J; Sun R; Wang X; Zhou X; Shang Y; Han Y
    Gastroenterol Hepatol; 2023 Nov; 46(9):692-701. PubMed ID: 36632973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial.
    Ishibashi S; Arai H; Yokote K; Araki E; Suganami H; Yamashita S;
    J Clin Lipidol; 2018; 12(1):173-184. PubMed ID: 29203092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience.
    Lemoinne S; Pares A; Reig A; Ben Belkacem K; Kemgang Fankem AD; Gaouar F; Poupon R; Housset C; Corpechot C; Chazouillères O
    Clin Res Hepatol Gastroenterol; 2018 Dec; 42(6):521-528. PubMed ID: 30100231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical and plasma lipid responses to pemafibrate in patients with primary biliary cholangitis.
    Joshita S; Umemura T; Yamashita Y; Sugiura A; Yamazaki T; Fujimori N; Matsumoto A; Tanaka E
    Hepatol Res; 2019 Oct; 49(10):1236-1243. PubMed ID: 31077509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Significant Increase of Estimated Glomerular Filtration Rate After Switching From Fenofibrate to Pemafibrate in Type 2 Diabetic Patients.
    Yanai H; Katsuyama H; Hakoshima M
    Cardiol Res; 2021 Dec; 12(6):358-362. PubMed ID: 34970366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis.
    Ida S; Kaneko R; Murata K
    Cardiovasc Diabetol; 2019 Mar; 18(1):38. PubMed ID: 30898163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial.
    Arai H; Yamashita S; Yokote K; Araki E; Suganami H; Ishibashi S;
    J Atheroscler Thromb; 2018 Jun; 25(6):521-538. PubMed ID: 29628483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of pemafibrate on primary biliary cholangitis with dyslipidemia.
    Yamaguchi M; Asano T; Arisaka T; Mashima H; Irisawa A; Tamano M
    Hepatol Res; 2022 Jun; 52(6):522-531. PubMed ID: 35072975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects on renal function and glucose metabolism of renal dependent bezafibrate and non-renal dependent pemafibrate in patients with hypertriglyceridemia.
    Nishida M; Horio T; Fukuda Y; Hayakawa Y; Tateishi Y; Akai M; Emoto M; Hasegawa T; Imanishi M
    Int J Clin Pharmacol Ther; 2023 Oct; 61(10):437-444. PubMed ID: 37548458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of switching to pemafibrate from bezafibrate in patients with chronic liver disease.
    Tamai H; Okamura J
    Hepatol Res; 2023 Mar; 53(3):258-266. PubMed ID: 36378065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of fibrates in cholestatic liver diseases.
    Carrion AF; Lindor KD; Levy C
    Liver Int; 2021 Jun; 41(6):1335-1343. PubMed ID: 33751787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis.
    Zhang Y; Li S; He L; Wang F; Chen K; Li J; Liu T; Zheng Y; Wang J; Lu W; Zhou Y; Yin Q; Xia Y; Zhou Y; Lu J; Guo C
    Drug Des Devel Ther; 2015; 9():2757-66. PubMed ID: 26045661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Pemafibrate Versus Fenofibrate Administration on Serum Lipid Levels in Patients with Dyslipidemia: Network Meta-Analysis and Systematic Review.
    Khan MS; Ghumman GM; Baqi A; Shah J; Aziz M; Mir T; Tahir A; Katragadda S; Singh H; Taleb M; Ali SS
    Am J Cardiovasc Drugs; 2023 Sep; 23(5):547-558. PubMed ID: 37524955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.